Advertisement

Topics

Genentech’s Actemra meets primary and secondary endpoints in Phase III trial for GCA

19:00 EDT 27 Jul 2017 | Net Resources International

Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA).

Original Article: Genentech’s Actemra meets primary and secondary endpoints in Phase III trial for GCA

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Actemra meets primary and secondary endpoints in Phase III trial for GCA"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...